2021 was a bright year for many pharmaceutical firms, especially those able to find widespread support for COVID-19 vaccines and therapies.
But it would be wrong to take a myopic view of the pandemic as a chief growth driver for leading drug developers. The most significant impact of the pandemic may be how it changed R&D rather than how it drove sales in 2021.
Three companies rounding out the top five — including the Chinese conglomerate Sinopharm, AbbVie and Novartis — didn’t have material COVID-19-related sales in 2021. The same holds for the bulk of companies in this year’s Pharma 50 report, which ranks the industry’s leading companies by overall revenue.
Get the full story from our sister site, Drug Discovery & Development.